Ifinatamab is a Monoclonal antibody targeting CD276, at Preclinical. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.

Maridebart is a Monoclonal antibody targeting GIPR, at Clinical. This 2026 report reviews clinical evidence, IP, deals, risks and a HOLD / OPTION view.

Trofinetide is a Synthetic peptide targeting IGF-1R, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Tofersen is a ASO targeting SOD1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Valbenazine Tosylate is a Small molecule drug targeting VMAT2, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Olintatug tesirine is a Antibody drug conjugate (ADC) targeting DNA x KAAG1, at Preclinical. This 2026 report reviews clinical evidence, IP, deals, risks.

Sebetralstat is a Small molecule drug targeting KLKB1, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Riluzole is a Small molecule drug targeting SCNA, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.

Solriamfetol Hydrochloride: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Delandistrogene moxeparvovec is a AAV based gene therapy targeting micro-dystrophin, at Approved. This 2026 report reviews clinical evidence, IP, deals.

Arimoclomol: Approved. 2026 diligence verdict: GO. Evidence review covers clinical, IP, deals, and risks.

Edaravone is a Small molecule drug targeting Free radicals, at Approved. This 2026 report reviews clinical evidence, IP, deals, risks and a GO view.